ERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1-mutated populations in post-CDK inhibitor setting, compared with standard of care plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback